128 filings
Page 2 of 7
6-K
zpt dmtvox
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
0uphynkg3rsz2tfr
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
6ap2oldumicy
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
q80vtb2z
27 May 22
ObsEva Announces Corporate Updates
4:56pm
6-K
klcq 5z6j
19 May 22
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
7:05am
6-K
jolpin
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
7pesslbnt1fb 35ysaeo
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
aw7lgpraf55pqt
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
ixdpi
7 Apr 22
ObsEva Annual General Meeting 2022
7:01am
6-K
kcttpjr
31 Mar 22
ObsEva Annual Report 2021
7:05am
6-K
qv7tqd8zxdehtxadyvl
22 Mar 22
Current report (foreign)
7:28am
6-K
0utco66bgoe hoz
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
6-K
ym9yet51g325z flyy15
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
kznad
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
0368aufpxgymqixl5i6
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
6-K
9ppy0j djb96
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
yu2jc tzcqu22mqj
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
q6f6c3
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
yg4q4
13 Dec 21
ObsEva Appoints Will Brown as Chief Financial Officer
7:00am
6-K
r5b9r78d
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am